Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease
Author:
Rucker Mary1, Fraites Thomas J.1, Porvasnik Stacy L.1, Lewis Melissa A.1, Zolotukhin Irene1, Cloutier Denise A.1, Byrne Barry J.1
Affiliation:
1. Powell Gene Therapy Center, and Departments of Molecular Genetics and Microbiology and Pediatrics, University of Florida College of Medicine,Gainesville, Florida 32610, USA
Abstract
Several human genetic diseases that affect striated muscle have been modeled by creating knockout mouse strains. However, many of these are perinatal lethal mutations that result in death from respiratory distress within hours after birth. As the diaphragm muscle does not contract until birth, the sudden increase in diaphragm activity creates permanent injury to the muscle causing it to fail to meet respiratory demands. Therefore, the impact of these mutations remains hidden throughout embryonic development and early death prevents investigators from performing detailed studies of other striated muscle groups past the neonatal stage. Glycogen storage disease type II (GSDII), caused by a deficiency in acid α-glucosidase (GAA), leads to lysosomal accumulation of glycogen in all cell types and abnormal myofibrillogenesis in striated muscle. Contractile function of the diaphragm muscle is severely affected in both infantile-onset and late-onset individuals, with death often resulting from respiratory failure. The knockout mouse model of GSDII survives well into adulthood despite the gradual weakening of all striated muscle groups. Using this model, we investigated the delivery of recombinant adeno-associated virus (rAAV) vectors encoding the human GAA cDNA to the developing embryo. Results indicate specific high-level transduction of diaphragm tissue, leading to activity levels up to 10-fold higher than normal and restoration of normal contractile function. Up to an estimated 50 vector copies per diploid genome were quantified in treated diaphragms. Histological glycogen staining of treated diaphragms revealed prevention of lysosomal glycogen accumulation in almost all fibers when compared with untreated controls. This method could be employed with disease models where specific rescue of the diaphragm would allow for increased survival and thus further investigation into the impact of the gene deletion on other striated muscle groups.
Publisher
The Company of Biologists
Subject
Developmental Biology,Molecular Biology
Reference50 articles.
1. Amalfitano, A., McVie-Wylie, A. J., Hu, H., Dawson, T. L.,Raben, N., Plotz, P. and Chen, Y. T. (1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc. Natl. Acad. Sci. USA96,8861-8866. 2. Amalfitano, A., Bengur, A. R., Morse, R. P., Majure, J. M.,Case, L. E., Veerling, D. L., Mackey, J., Kishnani, P., Smith, W.,McVie-Wylie, A. et al. (2001). Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med.3,132-138. 3. Brooks, S. V. and Faulkner, J. A. (1988). Contractile properties of skeletal muscles from young, adult and aged mice. J. Physiol.404,71-82. 4. Chen, Y. T. and Amalfitano, A. (2000). Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol. Med. Today6,245-251. 5. Cohen, J. C., Morrow, S. L., Cork, R. J., Delcarpio, J. B. and Larson, J. E. (1998). Molecular pathophysiology of cystic fibrosis based on the rescued knockout mouse model. Mol. Genet. Metab.64,108-118.
Cited by
63 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|